Revenue and Profitability - The Group recorded a revenue of RMB 15.6 million from maternal and child postpartum care industry services during the Period, reflecting a decline due to epidemic control measures[4]. - Revenue from the medical equipment and consumables trading business reached RMB 147.2 million, marking a significant growth in the Group's revenue structure[5]. - Total revenue for the six months ended June 30, 2023, was RMB 175,623,000, an increase from RMB 142,466,000 in the same period of 2022, representing a growth of approximately 23.2%[103]. - Income from postpartum care services was RMB 15,571,000 for the six months ended June 30, 2023, compared to RMB 24,712,000 in the same period of 2022, indicating a decline of about 37.1%[103]. - Profit attributable to owners of the Company decreased to approximately RMB 6.1 million for the six months ended June 30, 2023, down from RMB 8.1 million in the prior period[13]. - Profit before income tax for the six months ended June 30, 2023, was RMB 7,336,000, down from RMB 9,698,000 in the same period of 2022, reflecting a decrease of approximately 24.4%[103]. - Total comprehensive income for the period attributable to owners of the Company was RMB 6,115,000, compared to RMB 8,103,000 in the same period of 2022, indicating a decline of about 24.5%[103]. Expenses and Costs - Other operating expenses decreased from approximately RMB 24.4 million in the prior period to about RMB 21.0 million in the current period, primarily due to reduced miscellaneous expenses in the maternal and child postpartum care business[11]. - The Group's total employee costs for the period were approximately RMB 20.7 million, slightly up from RMB 20.6 million in the prior period[19]. - Staff costs for the six months ended June 30, 2023, were RMB 20,712,000, slightly increasing from RMB 20,639,000 in the same period of 2022, showing a marginal increase of about 0.4%[103]. Dividends and Shareholder Information - The Group does not recommend the payment of an interim dividend for the Period, consistent with the prior period[12]. - The final dividend declared for the period is HKD 0.025 per share, totaling HKD 10,000,000 (approximately RMB 9,140,000)[58]. - The ultimate controlling shareholders, Mr. Zhang Junshen and Mr. Zhang Junwei, are deemed to be interested in 75.0% of the issued share capital of the Company[1]. - Mr. Zhang Junshen holds 300,000,000 Shares, which includes 219,801,980 Shares held by Hero Global and 80,198,020 Shares as a party acting-in-concert with Mr. Zhang Junwei[2]. - Mr. Zhang Junwei also holds 300,000,000 Shares, consisting of 80,198,020 Shares held by Icon Global and 219,801,980 Shares as a party acting-in-concert with Mr. Zhang Junshen[3]. Financial Position and Assets - As of June 30, 2023, trade receivables amounted to RMB 100,091,000, down from RMB 132,435,000 as of December 31, 2022, indicating a reduction of approximately 24.3%[83]. - The company maintained a strong cash position with bank balances and cash totaling RMB 18,533,000 as of June 30, 2023, compared to RMB 13,707,000 at the end of 2022[128]. - The company’s total liabilities decreased from RMB 33,348,000 to RMB 28,500,000, a decline of approximately 14.5%[65]. - The net current assets as of June 30, 2023, were RMB 209,775,000, down from RMB 233,689,000 at the end of 2022[128]. - The total reportable segment assets as of June 30, 2023, amounted to RMB 532,483,000, with finance leasing assets at RMB 241,750,000, trading business assets at RMB 205,670,000, and postpartum care service assets at RMB 85,063,000[160]. Compliance and Governance - The Company has confirmed compliance with the Code of Conduct regarding securities transactions by the Directors for the reporting period[33]. - The Audit Committee has reviewed the unaudited condensed consolidated financial statements for the six months ended 30 June 2023, ensuring compliance with applicable accounting standards and GEM Listing Rules[54]. - The Company has adopted the corporate governance practices as per the GEM Listing Rules, ensuring proper regulation of business activities and decision-making processes[31]. - The independent non-executive Directors confirmed compliance with the Deed of Non-competition by all controlling shareholders during the period[44]. Market Outlook and Strategy - The Group anticipates that the health industry will become a new economic breakthrough point with significant value-added potential post-epidemic[5]. - The Group plans to continue increasing investment in various businesses despite the grim global economic situation[6]. - The management discussed strategies for market expansion and new product development, although specific figures were not disclosed in the provided content[89]. Cash Flow and Investments - Net cash generated from operating activities for the six months ended June 30, 2023, was RMB 21,481,000, compared to a net cash used of RMB 32,253,000 in the same period of 2022[136]. - Net cash used in investing activities was RMB 6,214,000 for the six months ended June 30, 2023, compared to a net cash generated of RMB 3,810,000 in the same period of 2022[136]. - The net decrease in cash and cash equivalents for the six months ended June 30, 2023, was RMB 41,810,000, an improvement from a decrease of RMB 68,487,000 in the same period of 2022[136]. Segment Performance - Reportable segment revenue for finance leasing service was RMB 4,975,000, while postpartum care service generated RMB 11,165,000, and trading of medical equipment and consumables reported a loss of RMB 832,000[143]. - Reportable segment profit before income tax for the same period was RMB 7,336,000, with a profit of RMB 2,749,000 from finance leasing, RMB 16,999,000 from trading, and a loss of RMB 2,208,000 from postpartum care services[160].
紫元元(08223) - 2023 - 中期财报